Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative to tumor tissue sequencing, and it is intended to specifically detect and sequence tumor DNA circulating in patients' blood. The results are used to help guide doctors to tailor the best treatment for patients at each point of their disease.
An international panel of experts has created a roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer.
A team headed by Xavier Salvatella, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), has discovered a new avenue through which to attack prostrate cancer cells that have developed drug resistance.
A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics specifically to cancer cells. Researchers used RNA nanotechnology to apply the RNA nanoparticles and control their orientation. The microscopic, therapy-loaded extracellular vesicles successfully targeted three types of cancer in animal models. The findings could lead to a new generation of anticancer drugs that use siRNA, microRNA and other RNA-interference technologies.
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
A new study from Keck Medicine of USC finds that data from a novel recorder can be used to objectively measure surgeons' proficiency in robotic-assisted prostate cancer surgery.
A team of researchers from The Scripps Research Institute (TSRI) and Duke University has made the first determination of the atomic structure of Transient Receptor Potential Melastatin 8 (TRPM8), a molecular sensor in nerve ends that detects cold temperatures as well as menthol and other chemicals that induce cold sensations.
New research shows how losing a ubiquitous gene opens genetic floodgates that make prostate cancer deadly, a finding that could apply to many cancers.
Researchers found that the one-month duration HRT, was associated with a significant improvement in prostate cancer recurrence compared to the two-month duration CRT and therefore would be reasonable to consider in men with intermediate risk prostate cancer who do not have risk factors that could predispose the patient to bladder side effects several years after the treatment is complete.
For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference. In a study featured in the December issue of The Journal of Nuclear Medicine, Australian researchers demonstrate that PET scans can identify which of these prostate cancer patients would benefit from salvage radiation treatment (SRT).